Bi-specific antibody therapy for the treatment of cancer

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 1, 2001, Pages 53-62

  Withoff, S ^a   Helfrich, W ^a   de Leij, L F M H ^a   Molema, G ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Bi specific antibodies; Immunotherapy; Recombinant antibodies; Tumor antigen

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CARBOHYDRATE DERIVATIVE; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CD20 ANTIGEN; CELL ANTIGEN; COMPLEMENT COMPONENT C1Q; CYTOKINE; CYTOKINE RECEPTOR; DIMER; DNA; EPITOPE; FC RECEPTOR; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; LIPOSOME; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; ONCOFETAL ANTIGEN; PROTEIN DERIVATIVE; RECOMBINANT ANTIBODY; RITUXIMAB; TRASTUZUMAB; TUMOR ANTIGEN; UNINDEXED DRUG;

ANTIBODY STRUCTURE; ANTIGEN RECOGNITION; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL ACTIVATION; CELL SPECIFICITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; EFFECTOR CELL; HUMAN; IMMUNOCOMPETENT CELL; RECOMBINANT DNA TECHNOLOGY; REVIEW; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, FC; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 0035113113     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Refined structure of an intact lgG2a monoclonal antibody
2. Divergent roles for Fc receptors and complement in vivo
3. Clinical trials of antibody therapy
4. The development of monoclonal antibodies for the therapy of cancer
5. Immunocytokines: A promising approach to cancer immunotherapy
6. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
7. Rituximab in indolent lymphoma: The single-agent pivotal trial
8. Preclinical and phase I and II trials of rituximab
9. Immunotherapeutic perspective for bispecific antibodies
10. How do cytotoxic lymphocytes kill their targets?
11. Function of CD3ε-mediated signals in T-cell development
12. Costimulatory regulation of T-cell function
13. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T-lymphocytes
14. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T-cells, tetravalent CD3 × CD19 tandem diabody, and CD28 costimulation
15. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T-cells
16. From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas
17. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2
18. Clinical experience with CD3xCD19 bispecific antibodies in patients with B-cell malignancies
19. CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro
20. CD3xCD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma
21. Purging of epithelial tumor cells from peripheral blood stem cells by means of the bispecific antibody BIS-1
22. Fc-γ-R-directed immunotherapies
23. Bispecific antibodies in cancer therapy
24. Human immunoglobulin A receptor (FcαRI, CD89) function in transgenic mice requires both FcR γ chain and CR3 (CD11b/CD18)
25. Bispecific molecules directed to the Fc receptor for IgA (Fc α RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood
26. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
27. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature
28. Genes expressed in human tumor endothelium
29. Vascular-specific growth factors and blood vessel formation
30. Optimism after much pessimism: What next?
31. Therapeutic monoclonal antibodies
32. Transgenic mice as a source of fully human antibodies for the treatment of cancer
33. Natural and designer binding sites made by phage display technology
34. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library
35. ScFv multimers of the anti-neuraminidase antibody NC10: Shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers
36. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: Effect of valency on cell binding
37. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris
38. High thermal stability is essential for tumor targeting of antibody fragments: Engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment
39. A dimeric bispecific miniantibody combines two specificities with avidity
40. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts
41. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen
42. Affinity enhancement of a recombinant antibody: Formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion
43. Formation of a bispecific antibody by the use of leucine zippers
44. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization
45. A rapid and versatile method for harnessing scFv antibody fragments with various biological effector functions
46. Construction and characterization of a bispecific diabody for retargeting T-cells to human carcinomas
47. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin γ1 Fc or CH3 region
48. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
49. Signaling events involved in anti-CD20-induced apoptosis of malignant human B-cells